XML 79 R58.htm IDEA: XBRL DOCUMENT
v3.8.0.1

SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Statements Of Operations) (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Revenues | $ 19,242 | $ 9,199 | $ 4,364
Pfizer [Member] |  |  |
Revenues | 12,181 | 5,226 |
BRAZIL |  |  |
Revenues | $ 7,061 | $ 3,973 | $ 4,364

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=plx_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |